Expertise in
89
conditions

Dr. Robert M. Rifkin

Internal Medicine
1800 N Williams St Ste 200, 
Denver, CO 
Accepting New Patients
Before you request
Expertise in
89
conditions
1800 N Williams St Ste 200, 
Denver, CO 

Overview

Robert Rifkin is a primary care provider, practicing in Internal Medicine in Denver, Colorado.

Dr. Rifkin is highly rated in 89 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Febrile Neutropenia, Agranulocytosis, and Mantle Cell Lymphoma (MCL).

Dr. Rifkin is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 72 peer reviewed articles and participating in 6 clinical trials. Dr. Rifkin is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in CO

Board Certifications

American Board Of Internal Medicine

Fellowships

University Of Arizona (fellowship)

Hospital Affiliations

Uchealth Broomfield Hospital
Uchealth Yampa Valley Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Silversummit Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Rocky Mountain Cancer Centers
1800 N Williams St Ste 200, Denver, CO 80218

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Enrollment Status: Terminated
Publish Date: May 04, 2026
Intervention Type: Drug
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 4
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Daratumumab, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide
Study Phase: Phase 2
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drugs: SEA-BCMA, Dexamethasone, Pomalidomide
Study Phase: Phase 1
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 26, 2022
Intervention Type: Drug
Study Drug: PT-112
Study Phase: Phase 1
View 5 Less Clinical Trials

72 Total Publications

Focal Hippocampal Onset and its Effect on Surgical Outcomes: A Case Report and Case Series.
Focal Hippocampal Onset and its Effect on Surgical Outcomes: A Case Report and Case Series.
Journal: Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
Published: August 03, 2026
Similar Doctors
Expertise in
7
conditions
Dr. Philip S. Mehler
Internal Medicine
Expertise in
7
conditions
Dr. Philip S. Mehler
Internal Medicine

Eating Recovery Center Denver-Franklin St.

1830 N Franklin St Ste 500, 
Denver, CO 
 (0.1 miles away)
303-731-8199
Languages Spoken:
English
See accepted insurances

Philip Mehler is a primary care provider, practicing in Internal Medicine in Denver, Colorado. Dr. Mehler is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Anorexia, Superior Mesenteric Artery Syndrome (SMAS), Bulimia, and Malnutrition.

Expertise in
18
conditions
Dr. Rohit K. Katial
Internal Medicine
Expertise in
18
conditions
Dr. Rohit K. Katial
Internal Medicine

National Jewish Health

1400 Jackson St, 
Denver, CO 
 (1.3 miles away)
303-398-1355
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rohit Katial is a primary care provider, practicing in Internal Medicine in Denver, Colorado. Dr. Katial is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Asthma, Eosinophilic Asthma, Simple Pulmonary Eosinophilia, and Chronic Eosinophilic Pneumonia. Dr. Katial is currently accepting new patients.

Expertise in
11
conditions
Dr. Kenneth L. Tyler
Internal Medicine
Expertise in
11
conditions
Dr. Kenneth L. Tyler
Internal Medicine

University Of Colorado Denver

12700 E 19th Ave, 
Aurora, CO 
 (6.6 miles away)
303-724-4327
Languages Spoken:
English

Kenneth Tyler is a primary care provider, practicing in Internal Medicine in Aurora, Colorado. Dr. Tyler is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Acute Flaccid Myelitis (AFM), Myelitis, Encephalitis, and Cramp-Fasciculation Syndrome.

Frequently Asked Questions about Dr. Robert M. Rifkin

How do I make an appointment with Dr. Robert M. Rifkin?

You can book an appointment with Dr. Robert M. Rifkin by calling their office at 303-388-4876. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Robert M. Rifkin a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Robert M. Rifkin is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Robert M. Rifkin specialize in?

While Dr. Robert M. Rifkin is a Internal Medicine, they have specific expertise in Multiple Myeloma, Febrile Neutropenia, and Agranulocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Robert M. Rifkin participate in research or clinical trials?

Yes. Dr. Robert M. Rifkin has published 72 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Robert M. Rifkin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Robert M. Rifkin accept my insurance?

Dr. Robert M. Rifkin accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 303-388-4876 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rifkin's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 76 Advanced Conditions
View All 155 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile